AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Hypercholesterolemia
Interventions
DRUG

Atorvastatin 20 mg

DRUG

AEGR-733 5 mg

DRUG

AEGR-733 10 mg

DRUG

Placebo

DRUG

AEGR-733 5 mg + atorvastatin 20 mg

DRUG

AEGR-733 10 mg + atorvastatin 20 mg

Trial Locations (17)

21209

Health Trends Research, Baltimore

23294

National Clinical Research, Richmond

23502

Hampton Roads Center for Clinical Research, Norfolk

27103

Piedmont Medical Research Associates, Winston-Salem

29445

Coastal Carolina Research Center, Goose Creek

30189

North Georgia Clinical Research, Woodstock

32205

Jacksonville Center for Clinical research, Jacksonville

32216

Jacksonville Center For Clinical Research, Jacksonville

34471

Renstar Medical Research, Ocala

35801

Medical Affiliated Research Center, Huntsville

45246

Sterling Research Group, Cincinnati

46260

Midwest Institute for Clinical Research, Indianapolis

47714

Medsphere Medical Research Center, Evansville

60610

Radiant Research, Chicago

75230

Dallas Diabetes and Endocrine Center, Dallas

78229

Diabetes and Glandular Disease Research, Dallas

04210

Maine Research Associates, Auburn

Sponsors
All Listed Sponsors
lead

Aegerion Pharmaceuticals, Inc.

INDUSTRY

NCT00474240 - AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia | Biotech Hunter | Biotech Hunter